Edwards Lifesciences Corp (EW) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Edwards Lifesciences’s revenue went from $3.0B in fiscal 2016 to $6.1B in fiscal 2025, growth of about 8.3% a year.
Net income in fiscal 2025 was $1.1B, a net margin of 17.7%; the best year in this period was 2024 with $4.2B.
Over the twelve months to September 30, 2026, revenue was $6.7B and net income $1.0B.
Free cash flow was $1.3B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 10% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.7B | $6.1B | $5.4B | $5.0B | $4.5B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B |
| Gross profit | $5.2B | $4.7B | $4.3B | $4.0B | $3.7B | $4.0B | $3.3B | $3.2B | $2.8B | $2.6B | $2.2B |
| Operating income | $1.4B | $1.3B | $1.4B | $1.3B | $1.5B | $1.7B | $898M | $1.1B | $748M | $1.1B | $751M |
| Net income | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | $823M | $1.0B | $722M | $584M | $570M |
| EPS (diluted) | $1.77 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.90 | $0.87 |
| R&D | $1.1B | $1.1B | $1.1B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M |
| Revenue growth | — | +11.6% | +8.6% | +12.2% | −14.7% | +19.3% | +0.9% | +16.8% | +8.4% | +15.9% | +18.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.7B | $1.6B | $542M | $896M | $1.2B | $1.7B | $1.1B | $1.2B | $927M | $1.0B | $704M |
| Capital spending | -$293M | -$260M | -$252M | -$253M | -$245M | -$326M | -$407M | -$254M | -$239M | -$168M | -$176M |
| Free cash flow | $1.4B | $1.3B | $290M | $643M | $974M | $1.4B | $647M | $928M | $688M | $833M | $528M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $755M | $893M | $1.2B | $880M | $1.7B | $513M | $625M | $263M | $796M | $763M | $662M |
| Stock-based pay | $173M | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $4.2B | $4.0B | $1.6B | $1.2B | $1.5B | $1.4B | $1.5B | $956M | $1.3B | $1.3B |
| Debt | — | $705M | $700M | $685M | $691M | $690M | $695M | $679M | $600M | $1.0B | $825M |
| Equity | — | $10.3B | $10.0B | $6.7B | $5.8B | $5.8B | $4.6B | $4.1B | $3.1B | $3.0B | $2.6B |
| Total assets | — | $13.7B | $13.1B | $9.4B | $8.3B | $8.5B | $7.2B | $6.5B | $5.3B | $5.7B | $4.5B |
| Shares (diluted) | 578M | 586M | 599M | 609M | 624M | 631M | 632M | 637M | 641M | 648M | 654M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 78.0% | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% |
| Operating margin | 21.6% | 20.8% | 25.4% | 26.1% | 33.6% | 32.3% | 20.5% | 26.4% | 20.1% | 31.7% | 25.4% |
| Net margin | 15.3% | 17.7% | 76.8% | 28.0% | 34.1% | 28.7% | 18.8% | 24.1% | 19.4% | 17.0% | 19.2% |
| FCF margin | 21.3% | 22.0% | 5.3% | 12.8% | 21.8% | 26.9% | 14.8% | 21.3% | 18.5% | 24.2% | 17.8% |
| ROIC | — | 9.5% | 11.6% | 15.9% | 20.1% | 22.9% | 15.3% | 21.3% | 19.0% | 15.4% | 16.8% |
| ROE | — | 10.4% | 41.8% | 21.1% | 26.2% | 25.8% | 18.0% | 25.2% | 23.0% | 19.7% | 21.7% |
Frequently asked questions
What is Edwards Lifesciences’s annual revenue?
$6.1B in fiscal 2025 and $6.7B over the twelve months to September 30, 2026.
How much profit does Edwards Lifesciences make?
Net income was $1.1B in fiscal 2025 (net margin 17.7%).
Is Edwards Lifesciences’s revenue growing?
Yes: revenue rose 11.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.